All In Biotech

Drug Trial Radar · NCT07944625

Clinical Trial to Evaluate the Protective Effect of Larazotide Acetate in Individuals With Well-Controlled Celiac Disease

A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Larazotide Acetate to Prevent Gluten-induced Celiac Enteropathy and Symptoms in Pediatric and Adult Participants With Well-Controlled Celiac Disease

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 414 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

414

Planned (sponsor's estimate)

Start

Feb 2027

Primary completion

Aug 2028

Study completion Sep 2028

Sponsor

Lead sponsor
Interlude Biopharma Co.Industry
Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if larazotide acetate, which will be tested at two doses and compared to placebo, can help prevent signs and symptoms of celiac disease in patients with well-controlled celiac disease who are following a gluten-free diet. Both adults and children (ages 12 years and up) will be allowed to enroll in this study.

Conditions

  • Celiac Disease
  • Celiac Disease in Adolescents

Interventions

  • Larazotide AcetateDrug

    Larazotide acetate will be taken as oral capsules TID, at the dose assigned per the study arm. Duration of treatment is 14 weeks.

  • PlaceboDrug

    Placebo capsules will be taken orally TID for 14 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of responders treatment with larazotide acetate (0.25 mg or 0.5 mg) compared to placebo during the last two weeks of the 14-week treatment periodTime frame: Last two weeks of the treatment period (Weeks 13-14)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.